Art

J-GLOBAL ID：201402233295029869   Reference number：14A1343082

High Expression of LMTK3 is an Independent Factor Indicating a Poor Prognosis in Estrogen Receptor α-Positive Breast Cancer Patients

LMTK3の高発現はエストロゲン受容体α陽性乳癌患者における予後不良を示す独立した因子である

Author (10)： ASANO Tomoko (Nagoya City Univ., Nagoya) ,  SATO Shinya (Nagoya City Univ., Nagoya) ,  SATO Shinya (Nagoya City East Medical Center, Nagoya, JPN) ,  YOSHIMOTO Nobuyasu (Nagoya City Univ., Nagoya) ,  ENDO Yumi (Nagoya City Univ., Nagoya) ,  HATO Yukari (Nagoya City Univ., Nagoya) ,  DONG Yu (Nagoya City Univ., Nagoya) ,  TAKAHASHI Satoru (Nagoya City Univ., Nagoya) ,  FUJII Yoshitaka (Nagoya City Univ., Nagoya) ,  TOYAMA Tatsuya (Nagoya City Univ., Nagoya)
Material： Japanese Journal of Clinical Oncology  (JJCO)
Volume： 44  Issue： 10  Page： 889-897  Publication year： Oct. 2014 
JST Material Number： W2222A  ISSN： 0368-2811  Document type： Article
Article type： 原著論文  Country of issue： United Kingdom (GBR)  Language： ENGLISH (EN)

Thesaurus term： human(primates) ,...
Semi thesaurus term： *LMTK3 ,...

Register(free) or Log In to access     To see more with JDream III (charged).   {{ this.onShowAbsJLink("http://jdream3.com/lp/jglobal/index.html?docNo=14A1343082&from=J-GLOBAL&jstjournalNo=W2222A") }}

JST classification (2)： Clinical oncology in general  (GE03010Y) ,  Proteins and peptides in general  (EB03010N)

Reference (20)：

• Harvey JM, Clark GM, Osborne CK, Allred DC. Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant endocrine therapy in breast cancer. J Clin Oncol 1999;17:1474-81.
• Early Breast Cancer Trialists’ Collaborative Group. Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 2005;365:1687-717.
• Giamas G, Filipovic A, Jacob J, et al. Kinome screening for regulators of the estrogen receptor identifies LMTK3 as a new therapeutic target in breast cancer. Nat Med 2011;17:715-9.
• Stebbing J, Filipovic A, Ellis IO, et al. LMTK3 expression in breast cancer: association with tumor phenotype and clinical outcome. Breast Cancer Res Treat 2012;132:537-44.
• Stebbing J, Filipovic A, Lit LC, et al. LMTK3 is implicated in endocrine resistance via multiple signaling pathways. Oncogene 2013;32:3371-80.

Terms in the title (6)： 発現 ,  エストロゲン受容体α ,  乳癌 ,  患者 ,  予後不良 ,  因子